FDA Approves Zepzelca® and Atezolizumab

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line
Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Click here to learn more.